Salvia Divinorum

Summary of the History and Significance of Salvia divinorum

Salvia divinorum is a perennial mint-family herb native to the cloud forests of the Sierra Mazateca in Oaxaca, Mexico. Among the Mazatec people, it is known as Ska María Pastora (Leaves of Mary the Shepherdess) and has been used for centuries in traditional healing and divinatory ceremonies. In these practices, fresh leaves are typically chewed or brewed into an infusion and consumed in quiet, dark settings under the guidance of a curandero (healer) to seek spiritual insight, diagnose illness, and communicate with the divine. Unlike peyote and psilocybin mushrooms, which have rich archaeological records,Salvia divinorum has a less documented history, likely due to its geographically restricted use and the relative isolation of the Mazatec from colonial and academic scrutiny until the mid-20th century.

Western scientific awareness of the plant began in the 1960s through ethnobotanist R. Gordon Wasson and anthropologist Jean Basset Johnson. Wasson collected specimens in Oaxaca, leading to the formal botanical description of Salvia divinorum by Carl Epling and Carlos D. Játiva in 1962. Substantial research lagged until the early 1980s, when Leander Valdés III, José Luis Díaz, and Ara G. Paul published a detailed pharmacognosy of the plant. In 1982, Alfredo Ortega isolated and characterized the primary active compound, salvinorin A, with its structure later confirmed by Valdés and colleagues. A major breakthrough came in 2002, when Bryan Roth and collaborators showed that salvinorin A is a potent, highly selective kappa-opioid receptor (KOR) agonist with negligible activity at serotonin receptors—an unprecedented mechanism among naturally occurring hallucinogens, which had previously been understood to act primarily via serotonergic pathways.

In the early 2000s,Salvia divinorum entered broader popular awareness as concentrated leaf extracts (e.g., 5x, 10x, 20x) became widely sold in head shops and online, primarily for smoking—an administration route not traditional in Mazatec use. Dramatic and often disorienting user experiences, frequently recorded and shared on early social media, drew intense public and media attention. This visibility prompted a wave of legislative responses between roughly 2005 and 2015, during which many U.S. states and several other countries imposed restrictions or outright bans on Salvia divinorum and salvinorin A. At the federal level in the United States, however, the plant and compound were not scheduled under the Controlled Substances Act, though the DEA designated them as a "Drug and Chemical of Concern."

Despite limited clinical translation, salvinorin A continues to attract academic and pharmaceutical interest due to its unique KOR selectivity. It has become an important research tool for probing kappa-opioid neurobiology, with implications for understanding and potentially treating conditions related to addiction, mood regulation, and pain.

Summary of Salvinorin A Pharmacology

Mechanism of Action

Salvinorin A is a highly selective, potent agonist at the kappa-opioid receptor (KOR) and is pharmacologically distinct from classic serotonergic psychedelics. It has:

• No meaningful activity at 5-HT2A receptors (primary target of LSD, psilocybin, mescaline)
• Negligible affinity for mu-and delta-opioid receptors

As the first known non-nitrogenous (non-alkaloid) opioid receptor ligand and the only naturally occurring hallucinogen acting exclusively via KOR, it produces a unique experiential profile. KOR activation is associated with:

• Dysphoria and mood disruption rather than euphoria
• Perceptual distortions and altered body perception
• Depersonalization and derealization
• A characteristic sense of being pulled, compressed, or merged with surroundings

These effects align with the kappa-opioid system’s role in modulating perception, mood, and states of consciousness.

Receptor Binding Profile

• Kappa-opioid receptor (KOR):
• Extremely high affinity and potency
• Active at sub-nanomolar concentrations
• Among the most potent known KOR agonists
• 5-HT2A:
• No significant binding
• Key distinction from classic psychedelics
• Mu-opioid receptor:
• Negligible affinity
• Does not produce typical mu-opioid effects (analgesia, euphoria, respiratory depression)
• Delta-opioid receptor:
• Negligible affinity
• Other systems (dopamine, GABA, glutamate):
• No significant direct receptor interaction
• Indirect effects on dopamine via KOR-mediated inhibition of dopaminergic neurons in the ventral tegmental area (VTA) are well documented

Pharmacokinetics

Inhalation (smoked/vaporized):

• Onset:30–60 seconds
• Peak:1–5 minutes
• Total duration:15–20 minutes
• Mechanism: High lipophilicity → rapid blood–brain barrier penetration → rapid redistribution and metabolism

Sublingual/buccal (chewed leaves, traditional use):

• Onset:10–20 minutes
• Duration:30–60 minutes
• Intensity: Generally milder peak than inhalation
• Absorption via oral mucosa partially bypasses first-pass hepatic metabolism

Oral ingestion (swallowed):

• Poor bioavailability
• Extensive first-pass metabolism in gut and liver by carboxylesterases→ largely inactive systemically

Metabolism:

• Rapid hydrolysis by carboxylesterases (primarily CES1) to salvinorin B
• Salvinorin B is inactive at KOR
• Fast metabolism explains the very short duration of action

Potency:

• Active inhaled dose:~200–500 micrograms
• Comparable in weight-based potency to LSD
• Considered the most potent naturally occurring hallucinogen known by mass

Summary of Salvia divinorum Safety Profile

Physiological Safety

• Salvinorin A has a high apparent physiological safety margin.
• No deaths have been directly linked to salvinorin A toxicity.
• Unlike serotonergic psychedelics or stimulants, it does not typically cause:
• Tachycardia
• Hypertension
• Despite being an opioid receptor agonist, it:
• Is kappa-opioid receptor (KOR) selective
• Does not cause respiratory depression (unlike mu-opioid agonists)
• Animal data suggest a high therapeutic index, but formal human safety pharmacology data remain limited.

Summary of Salvinorin A Human and Preclinical Research

Human Laboratory Studies

Johnson et al. — Johns Hopkins Dose-Response Study (2011)

A double-blind, placebo-controlled study in 4 experienced hallucinogen users tested ascending doses of inhaled salvinorin A (0.375–21 mcg/kg). Threshold psychoactive effects emerged at ~4 mcg/kg, with robust effects at 16–21 mcg/kg. Onset was rapid (peak within ~2 minutes) and effects largely resolved by 20 minutes. Subjective effects included intense perceptual alterations, spatial distortions, and dissociative phenomena, with minimal cardiovascular or other physiological changes. This work established the basic human pharmacology and dose–response characteristics of pure salvinorin A under controlled conditions.

Addy et al. — Naturalistic Salvia Use Survey (2012)

A survey of 500+ Salvia divinorum users characterized real-world patterns of use and subjective outcomes. Most respondents reported only 1–2 lifetime uses, consistent with low abuse liability. Experiences ranged from insightful and mood-improving to disturbing and aversive, with many users expressing no desire to repeat the experience. The study provided one of the first systematic, large-scale descriptions of salvinorin A experiences outside the lab.

MacLean et al. — Mystical Experience and Personality (2012)

Following the Johns Hopkins dose–response work, MacLean and colleagues examined how salvinorin A-induced states relate to mystical-type experiences and personality change. Compared with psilocybin, salvinorin A less frequently produced "complete mystical experiences" and was generally rated as less positive. Nonetheless, a subset of participants reported meaningful, sustained increases in openness to experience, suggesting potential for enduring psychological impact in some individuals.

Preclinical Research

KOR Agonism and Addiction

Preclinical studies highlight kappa-opioid receptor (KOR) signaling as a key modulator of addiction-related behaviors. Salvinorin A and KOR-selective analogs reduce self-administration and drug-seeking for cocaine, alcohol, and opioids in animal models. However, canonical KOR agonism is often dysphoric and aversive, posing a major translational barrier. Therapeutic strategies are therefore focusing on biased or partial KOR agonists that preserve anti-addictive effects while minimizing dysphoria and related side effects.

Nalfurafine and Biased KOR Agonists

The discovery of salvinorin A as a potent, selective KOR agonist helped catalyze efforts to design biased KOR ligands that favor beneficial signaling pathways (e.g., G-protein) over those linked to dysphoria (e.g., β-arrestin). Nalfurafine, a KOR agonist approved in Japan for pruritus, exemplifies a clinically used KOR-targeting drug emerging from this broader line of research, even though it is not directly derived from salvinorin A. Conceptually, these developments trace back to salvinorin A’s role in clarifying KOR pharmacology.

Current Clinical Status (as of early 2026)

There are no active clinical trials of salvinorin A or Salvia divinorum for psychiatric or other medical indications. At present, salvinorin A’s primary contribution is as a pharmacological probe: it has been crucial for dissecting KOR neurobiology and has inspired the design of novel KOR-targeted therapeutics, particularly biased agonists aimed at treating addiction and other neuropsychiatric conditions while avoiding classic KOR-mediated dysphoria.

Summary of Salvinorin A Clinical Translation Status

Pipeline Status

Salvinorin A currently has no active clinical development program. Its:

• Very short duration of action when smoked (5–20 minutes peak)
• Frequently dysphoric and unpleasant subjective effects
• Lack of a clear therapeutic niche compared with better-characterized psychedelics

have collectively limited interest in direct clinical development. No pharmaceutical company has publicly listed salvinorin A itself as a pipeline asset.

Key Research Directions Informed by Salvinorin A

1. Biased KOR Agonists

• Salvinorin A, as a potent and selective kappa-opioid receptor (KOR) agonist, helped reveal the therapeutic potential of KOR modulation.
• Current work focuses on G-protein–biased KOR agonists that favor G-protein signaling over beta-arrestin recruitment.
• Goal: retain beneficial KOR-mediated effects (e.g., anti-addiction, analgesic, anti-pruritic) while minimizing dysphoria and other adverse effects.
• Several academic and industry groups are pursuing such compounds, but few have reached clinical stages.

1. KOR Antagonists for Depression and SUDs

• While KOR agonism is associated with dysphoria,KOR antagonism shows antidepressant-like and anti-stress effects in preclinical models.
• CERC-501 (LY-2456302), a selective KOR antagonist, advanced to Phase II trials for depression and substance use disorders.
• Insights from salvinorin A’s KOR pharmacology directly contributed to the hypothesis that blocking KOR could be therapeutic in mood and addiction disorders.

1. Analgesic Applications

• KOR agonists can provide analgesia without the high abuse liability and respiratory depression typical of mu-opioid agonists.
• Salvinorin A analogs with modified pharmacokinetics (longer duration, reduced psychoactive intensity) are under preclinical investigation as non-addictive analgesics.

1. Neuroimaging and Consciousness Research

• Salvinorin A is a pure KOR agonist with negligible serotonergic activity, making it a useful tool to dissect the role of KOR vs. 5-HT2A and other systems.
• It serves as a contrast agent in neuroimaging and psychopharmacology studies comparing:
• Salvinorin A–induced states
• Psilocybin-induced (serotonergic psychedelic) states
• Ketamine-induced (NMDA antagonist) states
• These comparisons help clarify how different neurotransmitter systems shape altered states of consciousness and subjective experience.

Barriers to Direct Clinical Development of Salvinorin A

• Dysphoric Subjective Effects

KOR agonism often produces unpleasant, dysphoric experiences, limiting patient acceptability and therapeutic usability.

• Ultra-Short Duration of Action

The intense but brief 5–20 minute peak (especially via inhalation) may be operationally convenient but too short for many psychotherapeutic frameworks.

• Route of Administration Constraints
• Inhalation provides the most reliable and rapid delivery but is often impractical or undesirable in clinical settings.
• Buccal/sublingual routes are slower and less predictable, complicating dosing and session planning.
• Lack of Commercial Sponsorship

No major pharmaceutical sponsor has adopted salvinorin A as a development candidate.

Without a commercial champion,academic research alone is unlikely to drive full clinical translation (e.g., large Phase II/III trials and regulatory approval).

Overall

Salvinorin A’s primary impact is indirect and mechanistic rather than as a drug candidate itself. It has:

• Validated KOR as a target relevant to mood, addiction, pain, and consciousness.
• Inspired the development of biased KOR agonists,KOR antagonists, and salvinorin-derived analgesics.

However, its own pharmacology (dysphoria, ultra-short action, and delivery challenges) and the absence of industry backing have effectively stalled its direct clinical development.

Salvia divinorum and its active compound salvinorin A occupy a legally unusual position.

United States

At the federal level, neither Salvia divinorum nor salvinorin A is scheduled under the Controlled Substances Act. The DEA lists Salvia divinorum as a "Drug and Chemical of Concern", but has not placed it into any CSA schedule. As a result, under federal law it remains legal to possess, sell, and use.

At the state level, regulation is fragmented:

• Scheduled or banned:Delaware, Florida, Illinois, Kansas, Kentucky, Mississippi, Missouri, Nebraska, North Dakota, Ohio, Oklahoma, South Dakota, and Virginia classify Salvia divinorum and/or salvinorin A as controlled substances, in some cases equivalent to Schedule I.
• Age-restricted:Some states prohibit sales to minors or impose age limits without fully scheduling the substance.
• Unregulated/legal:Several states have no specific statutes addressing Salvia divinorum.

This patchwork of state laws without parallel federal scheduling is atypical for psychoactive substances and reflects Salvia’s ambiguous status: clearly psychoactive, with low demonstrated abuse potential and no recognized medical use.

International

Salvia divinorum is not scheduled under any of the major UN drug control treaties (1961 Single Convention, 1971 Convention on Psychotropic Substances). International control is therefore left to individual countries.

Examples:

• Controlled/banned:Australia (Schedule 9), Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, Italy, Japan, Latvia, Lithuania, Norway, Poland, Romania, South Korea, Spain, Sweden.
• Unregulated/legal:Many countries in South America, Southeast Asia, most of Africa, and some European states have no specific national controls.

Research Implications

Because Salvia divinorum and salvinorin A are not federally scheduled in the U.S., research is subject to fewer regulatory hurdles than work with Schedule I substances such as psilocybin, LSD, or MDMA. In states where Salvia is not scheduled, investigators do not need DEA Schedule I registrations to handle salvinorin A.

Despite this relative regulatory advantage, clinical and translational research has remained limited. The main obstacles appear to be:

• The compound’s intense, brief, and often challenging subjective effects
• Limited perceived commercial potential

These factors have likely outweighed the benefits of its comparatively permissive legal status.

Salvinorin A has negligible direct commercial value as a therapeutic product. Its primary importance is historical and mechanistic: it was a key tool compound that illuminated kappa-opioid receptor (KOR) neurobiology, but it is not itself a viable drug candidate due to its challenging, dysphoric, and short-acting subjective profile.

The meaningful commercial opportunity is entirely indirect, residing in the broader class of KOR-targeted therapeutics (biased agonists, partial agonists, antagonists) being developed for large, well-validated indications such as addiction, depression, pain, and pruritus. In this landscape:

• No pharmaceutical company is advancing salvinorin A itself in clinical development.
• Cara Therapeutics’ difelikefalin (Korsuva), a peripherally selective KOR agonist approved for pruritus in hemodialysis patients, demonstrates that KOR modulation can be commercially viable, even though it is not derived from salvinorin A.
• Janssen (J&J) and other large pharma players include KOR work within broader opioid receptor programs, reflecting strategic interest in KOR biology rather than in salvinorin A as a molecule.
• Academic groups (e.g., Johns Hopkins, Scripps Research) continue to refine understanding of KOR signaling, biased agonism, and circuit-level effects, which may seed future drug candidates and IP, but again with only an intellectual lineage back to salvinorin A.

The existing retail market for Salvia divinorum (leaf and extracts sold via head shops and online vendors) is small, shrinking, and commercially insignificant from a pharmaceutical or institutional investment standpoint. It does not represent a scalable or strategically relevant revenue stream.

In summary, salvinorin A’s commercial relevance is best viewed as foundational KOR pharmacology IP and know-how, not as a direct product opportunity. The real addressable markets—addiction, mood disorders, pain, and pruritus—are large, but the link to salvinorin A is conceptual rather than pipeline-based or royalty-bearing.

• Receptor-level split:
• Classic psychedelics: primarily 5-HT2A agonists → visual enhancement, emotional openness, mystical-type experiences, sense of meaning and interconnectedness.
• Salvinorin A: selective, high-efficacy kappa-opioid receptor (KOR) agonist → dysphoria, depersonalization, intense bodily distortions, pulling/compressing sensations, and often bizarre, immersive scene changes rather than classic geometric visuals.
• Salvinorin A vs. Ketamine:
• Mechanisms: KOR agonism (salvinorin A) vs. NMDA antagonism (ketamine).
• Subjective dissociation: ketamine is typically more “floaty,” anesthetic, and emotionally blunted; salvinorin A is more jarring, immersive, and often dysphoric or uncanny.
• Clinical status: ketamine/esketamine has robust clinical use (especially in depression and pain) and regulatory approval; salvinorin A remains preclinical with no established therapeutic indication.
• Salvinorin A vs. DMT:
• Both: ultra-rapid onset and short duration when smoked/vaporized; intense alterations of consciousness; frequent reports of entity-like encounters.
• Mechanisms: DMT is a classic 5-HT2A psychedelic (with additional receptor interactions); salvinorin A is purely KOR.
• Phenomenology: DMT tends toward hyper-visual, structured, often meaningful or mystical experiences; salvinorin A tends toward dysphoric, disorienting, and less “cosmologically coherent” states.
• Development: DMT is under active clinical and commercial development; salvinorin A is not, beyond early-stage or preclinical work.
• Salvinorin A vs. Ibogaine:
• Shared theme: both investigated for anti-addictive properties and both touch the opioid system.
• Mechanisms: salvinorin A is a relatively selective KOR agonist; ibogaine is highly polypharmacological (NMDA, KOR, sigma, SERT, and others), with a long, intense, oneirogenic experience.
• Evidence base: ibogaine has more clinical and observational data in addiction (despite safety concerns, especially cardiotoxicity); salvinorin A’s anti-addictive profile is mostly preclinical.
• Unique position of Salvinorin A:
• Only well-characterized, naturally occurring, highly potent hallucinogen that works via KOR rather than serotonergic 5-HT2A mechanisms.
• Helped establish KOR signaling as a lever for altering consciousness, dissociation, and affect, thereby enriching models of how different neuromodulatory systems shape subjective experience.
• Its main impact so far is conceptual and mechanistic (neuroscience, receptor pharmacology, models of dysphoria and dissociation) rather than clinical.